International Law Regulation of Access to Health Technologies
- 作者: Malichenko V.1
-
隶属关系:
- Institute of Legislation and Comparative Law under the Government of Russian Federation
- 期: 卷 14, 编号 5 (2021)
- 页面: 256-285
- 栏目: Law in the Modern World
- URL: https://journals.rcsi.science/2072-8166/article/view/318145
- DOI: https://doi.org/10.17323/2072-8166.2021.5.256.285
- ID: 318145
如何引用文章
全文:
详细
Over the past decades, the number of system challenges in health protection has rapidly increased, impacting every country, regardless of the economic well-being level. The situation is mainly driven by socio-demographic shocks, geopolitical instability, as well as the lack of a systematic approach to the development of legal regulation of the health sector at the international and national level. Health technologies are fundamental to providing health care, social care, and responding to natural and deliberate emergencies. Access to healthcare technologies is regulated by various branches of international law, which determines the complexity of this process, as well as the need to form special international legal mechanisms to ensure systematic counteraction to threats in the field of health protection, including emergencies. This article presents analysis of the access to health technologies role in rethinking the concept of human security at the international level, as well as in the framework of national security strategies. The author consistently examines the main directions for the development of health technologies transfer regulation, including the protection of the IP rights, the formation of global partnerships in the field of procurement, as well as the harmonization of legal regulation within the framework of regional economic integration initiatives. Special attention in the article is paid to the analysis of the main international regulation for data transfer and access to scientific knowledge necessary for health technologies transfer, as well as the assessment of national regulation. Based on the conducted analysis, the author formulates proposals for improving the international legal mechanisms regulating access to health technologies.
作者简介
Vladislav Malichenko
Institute of Legislation and Comparative Law under the Government of Russian Federation
Email: noreply@hse.ru
ORCID iD: 0000-0003-3136-8054
Candidate of Science (Law), Senior Researcher
参考
- Bermudez J., Hoen E. (2010) The UNITAID patent pool initiative: bringing patents together for the common good. The open AIDS Journal, vol. 4, pp. 37-40.
- Chien C. (2003) Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation? Berkeley Technology Law Journal, vol. 18, pp. 853-907.
- DiMasi J.A., Grabowski H.G. (2007) The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics, vol. 28, issue 4-5, pp. 469-479.
- DiMasi J.A., Hansen R.W., Grabowski H.G. (2003) The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics, vol. 22, issue 2, pp. 151-185.
- Dill S., Ahn J. (2014) Drug shortages in developed countries-reasons, therapeutic consequences, and handling. European Journal of Clinic Pharmacology, vol. 70, no. 12, pp. 1405-1412.
- Dosi G., Marengo L., Staccioli J., Virgillito M. (2021) Big pharma and monopoly capitalism: a long-term view. Pisa: Sant'Anna School of Advanced Studies, pp. 1-36.
- Dutfield G. (2003) Intellectual property rights and the life science industries: a twentieth century history. London: Routledge, 304 p.
- Mukherjee S. (2017) Emerging infectious diseases: Epidemiological perspective. Indian Journal of Dermatology, vol. 5, pp. 459-467.
- Plomer A. (2021) IP Rights and Human Rights. What History Tells Us and Why It Matters. The Right to Science. Cambridge: University Press, pp. 54-76.
- Ruikai D., Luanjiao H. (2021) Inclusive communications in COVID-19: a virtual ethnographic study of disability support network in China. Disability & Society, pp. 1-19.
- Schlander M., Hernandez-Villafuerte K., Cheng C. (2021) How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmaco Economics, vol. 39, pp. 1243-1269.
- Schweitzer S.O., Lu Z.J. (2018) Pharmaceutical economics and policy: perspectives, promises, and problems. Oxford: Oxford University Press, 432 p.
- Solovy E., Krishnamurthy P. (2017) TRIPS Agreement Flexibilities and Their Limitations: A Response to the UN Secretary-Generals' s High Level Panel Report on Access to Medicines. Geo. Wash. Int'l L. Review, vol. 50, pp. 1-19.
- Tucker E.L. et al. (2020) The Drug Shortage Era: A Scoping Review of the Literature 2001-2019. Clinic Pharmacology Therapy, vol. 108, pp. 1150-1155.
- White C. (2021) Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States. Journal of the American Pharmacists Association, vol. 1, pp. 93-98.
- Wirtz V.J., Hogerzeil H.V. et al. (2017) Essential medicines for universal health coverage. The Lancet, vol. 389, pp. 403-476.
- Yegros-Yegros A., Van de Klippe W., Abad-Garcia M.F., Rafols I. (2020) Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives. Health research policy and systems, no. 18, pp. 1-14.
补充文件
